Neurosensory Systems Group, Technical University of Darmstadt, Schnittspahnstrasse 3, 64287 Darmstadt, Germany.
Trends Pharmacol Sci. 2012 Aug;33(8):432-41. doi: 10.1016/j.tips.2012.05.002. Epub 2012 Jun 5.
Ivermectin is a gold standard antiparasitic drug that has been used successfully to treat billions of humans, livestock and pets. Until recently, the binding site on its Cys-loop receptor target had been a mystery. Recent protein crystal structures, site-directed mutagenesis data and molecular modelling now explain how ivermectin binds to these receptors and reveal why it is selective for invertebrate members of the Cys-loop receptor family. Combining this with emerging genomic information, we are now in a position to predict species sensitivity to ivermectin and better understand the molecular basis of ivermectin resistance. An understanding of the molecular structure of the ivermectin binding site, which is formed at the interface of two adjacent subunits in the transmembrane domain of the receptor, should also aid the development of new lead compounds both as anthelmintics and as therapies for a wide variety of human neurological disorders.
伊维菌素是一种金标准抗寄生虫药物,已成功用于治疗数十亿人类、牲畜和宠物。直到最近,其 Cys 环受体靶标的结合位点仍是一个谜。最近的蛋白质晶体结构、定点突变数据和分子建模现在解释了伊维菌素如何与这些受体结合,并揭示了为什么它对 Cys 环受体家族的无脊椎动物成员具有选择性。将这一点与新兴的基因组信息相结合,我们现在能够预测对伊维菌素的物种敏感性,并更好地理解伊维菌素耐药性的分子基础。对伊维菌素结合位点的分子结构的理解,该结合位点形成于受体跨膜域中两个相邻亚基的界面处,也应该有助于开发新的先导化合物,既可用作驱虫药,也可用作治疗各种人类神经紊乱的药物。